RECOMBINANT MONOCLONAL ANTIBODIES IN YEAST
The use of monoclonal antibodies (MABs) in diagnostic and therapeutics applications is on the rise; yet there are limitations to the current hybridoma technology. There is a need to develop less expensive, novel and improved technologies for MAb production. The application of recombinant technology has made it possible to generate single chain, chimeric and humanized MAbs with desired specificity. The goal of this SBIR Phase I proposal is to demonstrate utility of an efficient yeast expression system for production of a recombinant prototype MAbs. This will be achieved by construction of separate expression cassettes for the antibody H and L chains with a galactose regulated hybrid promoter, a leader sequence, and cDNAs for H or L chains. Both cassettes will be cloned into high copy yeast vector at two different cloning sites. This twin cassette plasmid will be transformed into yeast strains, the recombinant proteins produced will be confirmed by Western blot analysis. Thus at the end of Phase I, we would have proof of concept for the production of an improved system for Mabs using a reliable and inexpensive procedure. Phase II will include production of several MAbs of biomedical applications using this model yeast expression system.
Small Business Information at Submission:
Principal Investigator:Motwani, nalini m
100 RIVER PL, STE 6850 Detroit, MI 48207
Number of Employees: